Which of the following is an FDA-approved indication for latanoprost?

A. Conjunctivitis is an inflammatory or infectious process of the conjunctiva requiring antibiotics or antihistamines. Latanoprost does not possess antimicrobial or antiallergic properties. It is not indicated for the management of surface ocular infections or redness. B. Ocular inflammation is typically treated with topical corticosteroids or nonsteroidal anti-inflammatory drugs to inhibit arachidonic acid metabolites. Latanoprost is a prostaglandin F2-alpha analogue and does not reduce inflammatory cascades. It is not approved for uveitis or post-surgical inflammation. C. Elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension is the primary indication. Latanoprost increases the uveoscleral outflow of aqueous humor by remodeling the extracellular matrix. This physiological shift effectively reduces the internal pressure of the eye. D. Closed-angle glaucoma is a medical emergency that often requires surgical intervention or different pharmacological mechanisms. Latanoprost is specifically labeled for open-angle glaucoma where the drainage angle remains physically open. It is not the standard primary treatment for acute angle-closure.